436 related articles for article (PubMed ID: 25407545)
1. Rifampicin loaded mannosylated cationic nanostructured lipid carriers for alveolar macrophage-specific delivery.
Song X; Lin Q; Guo L; Fu Y; Han J; Ke H; Sun X; Gong T; Zhang Z
Pharm Res; 2015 May; 32(5):1741-51. PubMed ID: 25407545
[TBL] [Abstract][Full Text] [Related]
2. Delivery of rifampicin-PLGA microspheres into alveolar macrophages is promising for treatment of tuberculosis.
Hirota K; Hasegawa T; Nakajima T; Inagawa H; Kohchi C; Soma G; Makino K; Terada H
J Control Release; 2010 Mar; 142(3):339-46. PubMed ID: 19951729
[TBL] [Abstract][Full Text] [Related]
3. One-step preparation of rifampicin/poly(lactic-co-glycolic acid) nanoparticle-containing mannitol microspheres using a four-fluid nozzle spray drier for inhalation therapy of tuberculosis.
Ohashi K; Kabasawa T; Ozeki T; Okada H
J Control Release; 2009 Apr; 135(1):19-24. PubMed ID: 19121349
[TBL] [Abstract][Full Text] [Related]
4. Targeted macrophages delivery of rifampicin-loaded lipid nanoparticles to improve tuberculosis treatment.
Vieira AC; Magalhães J; Rocha S; Cardoso MS; Santos SG; Borges M; Pinheiro M; Reis S
Nanomedicine (Lond); 2017 Dec; 12(24):2721-2736. PubMed ID: 29119867
[TBL] [Abstract][Full Text] [Related]
5. Size-exclusive effect of nanostructured lipid carriers on oral drug delivery.
Li H; Chen M; Su Z; Sun M; Ping Q
Int J Pharm; 2016 Sep; 511(1):524-537. PubMed ID: 27452421
[TBL] [Abstract][Full Text] [Related]
6. Quality by Design (QbD)-enabled development of aceclofenac loaded-nano structured lipid carriers (NLCs): An improved dermatokinetic profile for inflammatory disorder(s).
Garg NK; Sharma G; Singh B; Nirbhavane P; Tyagi RK; Shukla R; Katare OP
Int J Pharm; 2017 Jan; 517(1-2):413-431. PubMed ID: 27956192
[TBL] [Abstract][Full Text] [Related]
7. Efficient intracellular delivery of rifampicin to alveolar macrophages using rifampicin-loaded PLGA microspheres: effects of molecular weight and composition of PLGA on release of rifampicin.
Makino K; Nakajima T; Shikamura M; Ito F; Ando S; Kochi C; Inagawa H; Soma G; Terada H
Colloids Surf B Biointerfaces; 2004 Jul; 36(1):35-42. PubMed ID: 15261021
[TBL] [Abstract][Full Text] [Related]
8. Nose to Brain Delivery of Rivastigmine by In Situ Gelling Cationic Nanostructured Lipid Carriers: Enhanced Brain Distribution and Pharmacodynamics.
Wavikar P; Pai R; Vavia P
J Pharm Sci; 2017 Dec; 106(12):3613-3622. PubMed ID: 28923321
[TBL] [Abstract][Full Text] [Related]
9. Preparation and Characterization of Minoxidil Loaded Nanostructured Lipid Carriers.
Wang W; Chen L; Huang X; Shao A
AAPS PharmSciTech; 2017 Feb; 18(2):509-516. PubMed ID: 27120090
[TBL] [Abstract][Full Text] [Related]
10. Mannosylated nanoparticulate carriers of rifabutin for alveolar targeting.
Nimje N; Agarwal A; Saraogi GK; Lariya N; Rai G; Agrawal H; Agrawal GP
J Drug Target; 2009 Dec; 17(10):777-87. PubMed ID: 19938949
[TBL] [Abstract][Full Text] [Related]
11. Enhanced antifungal activity of voriconazole-loaded nanostructured lipid carriers against
Tian B; Yan Q; Wang J; Ding C; Sai S
Int J Nanomedicine; 2017; 12():7131-7141. PubMed ID: 29026306
[No Abstract] [Full Text] [Related]
12. Effect of surface charge on the brain delivery of nanostructured lipid carriers in situ gels via the nasal route.
Gabal YM; Kamel AO; Sammour OA; Elshafeey AH
Int J Pharm; 2014 Oct; 473(1-2):442-57. PubMed ID: 25062866
[TBL] [Abstract][Full Text] [Related]
13. Preparation, Pharmacokinetics, and Antitumor Potential of Miltefosine-Loaded Nanostructured Lipid Carriers.
Yu G; Ali Z; Sajjad Khan A; Ullah K; Jamshaid H; Zeb A; Imran M; Sarwar S; Choi HG; Ud Din F
Int J Nanomedicine; 2021; 16():3255-3273. PubMed ID: 34012260
[TBL] [Abstract][Full Text] [Related]
14. Effect of liquid-to-solid lipid ratio on characterizations of flurbiprofen-loaded solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs) for transdermal administration.
Song A; Zhang X; Li Y; Mao X; Han F
Drug Dev Ind Pharm; 2016 Aug; 42(8):1308-14. PubMed ID: 26707734
[TBL] [Abstract][Full Text] [Related]
15. Preparation and characterization of dutasteride-loaded nanostructured lipid carriers coated with stearic acid-chitosan oligomer for topical delivery.
Noor NM; Sheikh K; Somavarapu S; Taylor KMG
Eur J Pharm Biopharm; 2017 Aug; 117():372-384. PubMed ID: 28412472
[TBL] [Abstract][Full Text] [Related]
16. Vincristine and temozolomide combined chemotherapy for the treatment of glioma: a comparison of solid lipid nanoparticles and nanostructured lipid carriers for dual drugs delivery.
Wu M; Fan Y; Lv S; Xiao B; Ye M; Zhu X
Drug Deliv; 2016 Oct; 23(8):2720-2725. PubMed ID: 26203691
[TBL] [Abstract][Full Text] [Related]
17. Lipid microsphere formulation containing rifampicin targets alveolar macrophages.
Takenaga M; Ohta Y; Tokura Y; Hamaguchi A; Igarashi R; Disratthakit A; Doi N
Drug Deliv; 2008; 15(3):169-75. PubMed ID: 18379929
[TBL] [Abstract][Full Text] [Related]
18. Curcumin-guided nanotherapy: a lipid-based nanomedicine for targeted drug delivery in breast cancer therapy.
Lin M; Teng L; Wang Y; Zhang J; Sun X
Drug Deliv; 2016 May; 23(4):1420-5. PubMed ID: 26203688
[TBL] [Abstract][Full Text] [Related]
19. Dry-Powder Inhaler Formulation of Rifampicin: An Improved Targeted Delivery System for Alveolar Tuberculosis.
Rawal T; Kremer L; Halloum I; Butani S
J Aerosol Med Pulm Drug Deliv; 2017 Dec; 30(6):388-398. PubMed ID: 28510480
[TBL] [Abstract][Full Text] [Related]
20. Enhanced transdermal delivery of lornoxicam by nanostructured lipid carrier gels modified with polyarginine peptide for treatment of carrageenan-induced rat paw edema.
Gao S; Tian B; Han J; Zhang J; Shi Y; Lv Q; Li K
Int J Nanomedicine; 2019; 14():6135-6150. PubMed ID: 31447556
[No Abstract] [Full Text] [Related]
[Next] [New Search]
